AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18765046 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 80
Study 16186467 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEEs)
Number of subjects: 10739
Study 12673431 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised CONSORT statement
Number of subjects: 0
Study 12673431 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist and flow diagram
Number of subjects: 0
Study 12673431 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow diagram
Number of subjects: 0
Study 10621528 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir as prophylaxis against recurrent stromal keratitis
Number of subjects: 0
Study 8659620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment of residual symptoms
Number of subjects: 40
Study 8659620 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical management
Number of subjects: 40
Study 29150861 — intervention group
Group type: EXPERIMENTAL
Intervention: HypoAware intervention (blended psycho-educational intervention)
Number of subjects: 137
Study 29150861 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 137
Study 27311902 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to electronic brief intervention (eBI)
Number of subjects: 746
Study 27311902 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face advice
Number of subjects: 746
Study 27311902 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to eBI
Number of subjects: 746
Study 23824500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar diagnosed participants
Number of subjects: 190
Study 23824500 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD diagnosed participants
Number of subjects: 190
Study 23824500 — intervention group
Group type: COMPARATOR
Intervention: ADHD diagnosed participants
Number of subjects: 190
Study 23824500 — intervention group
Group type: COMPARATOR
Intervention: Matched comparison samples
Number of subjects: 190
Study 22626491 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 593
Study 22626491 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 593
Study 21169002 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (CysLT receptor 1 antagonist)
Number of subjects: 37
Study 21169002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 18022545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine therapy
Number of subjects: 0
Study 18022545 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15598669 — intervention group
Group type: EXPERIMENTAL
Intervention: ORAL
Number of subjects: 36
Study 15598669 — intervention group
Group type: EXPERIMENTAL
Intervention: DEPO
Number of subjects: 36
Study 15598669 — intervention group
Group type: COMPARATOR
Intervention: EU-OV
Number of subjects: 36
Study 15598669 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPT (all groups)
Number of subjects: 36
Study 11948850 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapina (test formulation)
Number of subjects: 25
Study 11948850 — intervention group
Group type: COMPARATOR
Intervention: Viramune (reference formulation)
Number of subjects: 25
Study 10407237 — intervention group
Group type: EXPERIMENTAL
Intervention: Continual low dose corticosteroid treatment
Number of subjects: 0
Study 10407237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8534439 — intervention group
Group type: EXPERIMENTAL
Intervention: Perkins tonometer
Number of subjects: 73
Study 8534439 — intervention group
Group type: EXPERIMENTAL
Intervention: Schiotz tonometer
Number of subjects: 73
Study 8534439 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonopen tonometer
Number of subjects: 73
Study 8534439 — intervention group
Group type: COMPARATOR
Intervention: Goldmann Applanation tonometer (gold standard)
Number of subjects: 73
Study 8534439 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments (funduscopy, gonioscopy, repeat measurement of intraocular pressure, visual field assessment)
Number of subjects: 73
Study 8534439 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice patients
Number of subjects: 73
Study 2076222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrice (1100 ppm F)
Number of subjects: 15
Study 2076222 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 15
Study 511419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 0.2 mg/kg body weight pirenzepine
Number of subjects: 16
Study 511419 — intervention group
Group type: COMPARATOR
Intervention: Solvent injection (control)
Number of subjects: 16
Study 31408791 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 60
Study 31408791 — intervention group
Group type: COMPARATOR
Intervention: cTBS
Number of subjects: 60
Study 31408791 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 60
Study 27613719 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based step aerobics exercise (EG)
Number of subjects: 48
Study 27613719 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 48
Study 26350550 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy‐assisted gastrectomy (LAG)
Number of subjects: 270
Study 26350550 — intervention group
Group type: COMPARATOR
Intervention: Conventional open gastrectomy (OG)
Number of subjects: 270
Study 24156306 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (12 mmol/l citrate, HCO3- 32 mmol/l replacement fluid)
Number of subjects: 40
Study 24156306 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (18 mmol/l citrate with phosphate-containing dialysate/replacement fluid, HCO3- 30 mmol/l, Phosphate 1.2)
Number of subjects: 40
Study 21335007 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFN therapy
Number of subjects: 813
Study 21335007 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 813
Study 21335007 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline stainable iron in hepatocytes and portal tract cells
Number of subjects: 813
Study 21335007 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron in triads at baseline
Number of subjects: 813
Study 21335007 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainable iron in hepatocytes
Number of subjects: 813
Study 21335007 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainable iron in portal stromal cells
Number of subjects: 813
Study 21335007 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum iron and TIBC
Number of subjects: 813
Study 21335007 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin
Number of subjects: 813
Study 21335007 — intervention group
Group type: EXPERIMENTAL
Intervention: HFE genetic variations
Number of subjects: 813
Study 19352198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300-450 mg/day
Number of subjects: 301
Study 19352198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 301
Study 19352198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day
Number of subjects: 301
Study 19352198 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (alprazolam 1.5 mg/day; lorazepam 6 mg/day)
Number of subjects: 301
Study 19352198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 16723311 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 1 containing 250 mg vitamin C
Number of subjects: 39
Study 16723311 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 2 containing 250 mg vitamin C
Number of subjects: 39
Study 16723311 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 3 containing 250 mg vitamin C
Number of subjects: 39
Study 16723311 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study 15167335 — intervention group
Group type: COMPARATOR
Intervention: Hooks in claw configuration in both the thoracic and lumbar spine (group A)
Number of subjects: 40
Study 15167335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hooks in thoracic vertebrae and pedicle screws in lumbar vertebrae (group B)
Number of subjects: 40
Study 15167335 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 40
Study 10902623 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoms available in rooms
Number of subjects: 6463
Study 10902623 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly handing condoms to couples
Number of subjects: 6463
Study 10902623 — intervention group
Group type: EXPERIMENTAL
Intervention: Health‐education material present
Number of subjects: 6463
Study 10902623 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoms on request
Number of subjects: 6463
Study 9315597 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pravastatin combined with low-dose cholestyramine
Number of subjects: 59
Study 9315597 — intervention group
Group type: COMPARATOR
Intervention: High-dose pravastatin monotherapy
Number of subjects: 59
Study 10148847 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (HCC)
Number of subjects: 24
Study 10148847 — intervention group
Group type: COMPARATOR
Intervention: Non-coated circuits (NCC)
Number of subjects: 24
Study 3518638 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% isotretinoin gel
Number of subjects: 20
Study 3518638 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 20
Study 29579195 — intervention group
Group type: EXPERIMENTAL
Intervention: MST3 (3 rounds of mass screening and treatment)
Number of subjects: 1870
Study 29579195 — intervention group
Group type: EXPERIMENTAL
Intervention: MST2 (2 rounds of mass screening and treatment)
Number of subjects: 1870
Study 29579195 — intervention group
Group type: COMPARATOR
Intervention: MST0 (no mass screening and treatment)
Number of subjects: 1870
Study 27076772 — intervention group
Group type: EXPERIMENTAL
Intervention: Active care (6 mo colonoscopy and drug intensification for endoscopic recurrence)
Number of subjects: 60
Study 27076772 — intervention group
Group type: COMPARATOR
Intervention: Standard care (drug therapy without early endoscopy)
Number of subjects: 60
Study 27076772 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy at 18 mo and faecal calprotectin (FC) measurement
Number of subjects: 60
Study 25420889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LS) 30mg once daily for 4 weeks
Number of subjects: 90
Study 25420889 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (LS) 30mg once daily for 1 week followed by Ecabet Sodium (ES) 1500mg twice daily for 3 weeks
Number of subjects: 90
Study 23539933 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 34
Study 23539933 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 34
Study 20723034 — intervention group
Group type: EXPERIMENTAL
Intervention: Terutroban 1 mg day(-1)
Number of subjects: 435
Study 20723034 — intervention group
Group type: EXPERIMENTAL
Intervention: Terutroban 2.5 mg day(-1)
Number of subjects: 435
Study 20723034 — intervention group
Group type: EXPERIMENTAL
Intervention: Terutroban 5 mg day(-1)
Number of subjects: 435
Study 20723034 — intervention group
Group type: EXPERIMENTAL
Intervention: Terutroban 10 mg day(-1)
Number of subjects: 435
Study 20723034 — intervention group
Group type: EXPERIMENTAL
Intervention: Terutroban 30 mg day(-1)
Number of subjects: 435
Study 20723034 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 75 mg day(-1)
Number of subjects: 435
Study 20723034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 18942055 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 89
Study 18942055 — intervention group
Group type: COMPARATOR
Intervention: Anterior 180 degrees partial fundoplication
Number of subjects: 89
Study 15892271 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI) plus chemotherapy (CT)
Number of subjects: 65
Study 15892271 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT) only
Number of subjects: 65
Study 12322846 — intervention group
Group type: EXPERIMENTAL
Intervention: Enaril 5 mg tablets
Number of subjects: 14
Study 10426610 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (200 microg tablet for at least four hours)
Number of subjects: 199
Study 10426610 — intervention group
Group type: COMPARATOR
Intervention: Vaginal gemeprost (1.0 mg vaginal suppository for at least three hours)
Number of subjects: 199
Study 10426610 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 199
Study 10426610 — intervention group
Group type: COMPARATOR
Intervention: Vaginal gemeprost
Number of subjects: 199
Study 10426610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 199
Study 7897139 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 0
Study 7897139 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy or implantable cardioverter‐defibrillator therapy
Number of subjects: 0
Study 2258063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP) with bacillus Calmette-Guerin (BCG)
Number of subjects: 411
Study 2258063 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP) without bacillus Calmette-Guerin (BCG)
Number of subjects: 411
Study 6263139 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions
Number of subjects: 46
Study 30888737 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTX‐4975 0.5 mg
Number of subjects: 172
Study 30888737 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTX‐4975 1.0 mg
Number of subjects: 172
Study 30888737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 29485309 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral isokinetic resistance training of the knee extensors for 4 weeks
Number of subjects: 42
Study 28984010 — intervention group
Group type: EXPERIMENTAL
Intervention: rhFVIIa 25 μg/kg
Number of subjects: 30
Study 28984010 — intervention group
Group type: EXPERIMENTAL
Intervention: rhFVIIa 75 μg/kg
Number of subjects: 30
Study 28984010 — intervention group
Group type: EXPERIMENTAL
Intervention: rhFVIIa 225 μg/kg
Number of subjects: 30
Study 28984010 — intervention group
Group type: EXPERIMENTAL
Intervention: rhFVIIa (all doses)
Number of subjects: 30
Study 25927288 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-limb high-repetitive resistance training with elastic bands, three times/week for 8 weeks
Number of subjects: 0
Study 25927288 — intervention group
Group type: COMPARATOR
Intervention: Two-limb high-repetitive resistance training with elastic bands, three times/week for 8 weeks
Number of subjects: 0
Study 25927288 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-limb high-repetitive resistance training
Number of subjects: 0
Study 25927288 — intervention group
Group type: COMPARATOR
Intervention: Two-limb high-repetitive resistance training
Number of subjects: 0
Study 23489513 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy (PNL)
Number of subjects: 80
Study 23489513 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ureterolithotomy (LUL)
Number of subjects: 80
Study 21472665 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 66
Study 21472665 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 66
Study 21472665 — intervention group
Group type: COMPARATOR
Intervention: Control (optimal diet therapy, sulfonylurea and/or insulin)
Number of subjects: 66
Study 18604552 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasonography in 400 patients (Group A) to identify arterial abnormalities associated with nonrecurrent ILN.
Number of subjects: 750
Study 18604552 — intervention group
Group type: COMPARATOR
Intervention: No preoperative ultrasonography in 350 patients (Group B).
Number of subjects: 750
Study 18604552 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasonography in Group A.
Number of subjects: 750
Study 18604552 — intervention group
Group type: COMPARATOR
Intervention: No preoperative ultrasonography in Group B.
Number of subjects: 750
Study 16607061 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based dentin sealer applied following manufacturer's recommendations
Number of subjects: 62
Study 16607061 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 62
Study 12518133 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look endoscopy with retreatment
Number of subjects: 0
Study 12518133 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 0
Study 11273919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl bolus (Group 1)
Number of subjects: 45
Study 11273919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl continuous infusion (Group 2)
Number of subjects: 45
Study 11273919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam infusion (Group 3)
Number of subjects: 45
Study 11273919 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 45
Study 9298429 — intervention group
Group type: EXPERIMENTAL
Intervention: Primarily noradrenergic reuptake inhibitor (desipramine)
Number of subjects: 158
Study 9298429 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) (sertraline or paroxetine)
Number of subjects: 158
Study 9298429 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined serotonin and norepinephrine reuptake inhibitor (SNRI) (venlafaxine)
Number of subjects: 158
Study 8420442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (10 mg initial oral daily dose, then 20 mg once a day during open-label phase)
Number of subjects: 26
Study 8420442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (during extended open-label phase)
Number of subjects: 26
Study 8420442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3521428 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 40
Study 3521428 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine isethionate
Number of subjects: 40
Study 30118997 — intervention group
Group type: EXPERIMENTAL
Intervention: Genu Varum deformity (GVD) group
Number of subjects: 44
Study 30118997 — intervention group
Group type: COMPARATOR
Intervention: Healthy group (without GVD)
Number of subjects: 44
Study 26696613 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 4187
Study 26696613 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4187
Study 24819566 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin (10 μg/kg, 1×/week subcutaneously)
Number of subjects: 102
Study 24819566 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (400 U/kg, 3×/week subcutaneously)
Number of subjects: 102
Study 24819566 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham dosing 3×/week)
Number of subjects: 102
Study 22535517 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 21
Study 22535517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20536518 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated haemoglobin (HbA1c) <7.0%
Number of subjects: 1153
Study 20536518 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated haemoglobin (HbA1c) <8.0%
Number of subjects: 1153
Study 20536518 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of aspirin
Number of subjects: 1153
Study 20536518 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of ACE inhibitors or ARBs
Number of subjects: 1153
Study 20536518 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of statins
Number of subjects: 1153
Study 20536518 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of statins in LDL >3.4 mmol/l
Number of subjects: 1153
Study 18395397 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Angina Self-Management Program (CASMP)
Number of subjects: 130
Study 18395397 — intervention group
Group type: COMPARATOR
Intervention: Wait-list usual care (control)
Number of subjects: 130
Study 15677610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (subanesthetic dose)
Number of subjects: 10
Study 15677610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12924802 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic knee sleeve
Number of subjects: 0
Study 12924802 — intervention group
Group type: COMPARATOR
Intervention: Control group (acetaminophen, NSAIDs, and education)
Number of subjects: 0
Study 10640258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolmitriptan
Number of subjects: 2499
Study 10640258 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg zolmitriptan
Number of subjects: 2499
Study 10640258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2499
Study 10640258 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan (2.5 mg or 5 mg)
Number of subjects: 2499
Study 10640258 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan (5 mg)
Number of subjects: 2499
Study 9552521 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty with a postangioplasty diameter stenosis less than 30%
Number of subjects: 0
Study 9552521 — intervention group
Group type: COMPARATOR
Intervention: Palmaz-Schatz stent implantation
Number of subjects: 0
Study 2669067 — intervention group
Group type: EXPERIMENTAL
Intervention: APD (300 mg/day orally)
Number of subjects: 131
Study 2669067 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 131
Study 71972 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg daily
Number of subjects: 15
Study 71972 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen 150 mg daily plus 3 g aspirin daily
Number of subjects: 15
Study 29239988 — intervention group
Group type: EXPERIMENTAL
Intervention: With boards (WBs)
Number of subjects: 11
Study 29239988 — intervention group
Group type: COMPARATOR
Intervention: Without boards (WOBs)
Number of subjects: 11